论文部分内容阅读
目的讨论研究IEA方案与FLAG方案治疗难治性急性淋巴细胞白血病的疗效对比。方法将本院40例难治性淋巴细胞白血病患者分为甲组、乙组,各20例。甲组采用IEA方案,治疗药物包括善为达,足叶乙苷,阿糖胞苷;乙组予以FLAG方案,治疗药物包括氟达拉滨,阿糖胞苷,粒细胞集落刺激因子。观察对比两组患者疗效及不良反应等指标。结果两组患者治疗后死亡率及并发症发生率的比较显示甲组并发症发生率45.0%与死亡率10.0%均低于乙组并发症发生率65.0%与死亡率25.0%,结果具有统计学意义(P<0.05),甲、乙两组应用不同治疗方案后疗效差异不大。结论 IEA方案治疗难治性急性淋巴细胞白血病,疗效肯定,作用明显,副作用少,值得临床予以推广使用。
Objective To compare the efficacy of IEA and FLAG in the treatment of refractory acute lymphoblastic leukemia. Methods 40 cases of refractory lymphoblastic leukemia in our hospital were divided into group A and group B, 20 cases each. Group A using IEA program, the treatment of drugs, including good for, etoposide, cytarabine; B group to FLAG program, the treatment of drugs including fludarabine, cytarabine, granulocyte colony stimulating factor. Observed and compared two groups of indicators of efficacy and adverse reactions. Results Comparisons of post-treatment mortality and complication rates between the two groups showed that the incidence of complication and mortality in group A were 45.0% and 10.0%, respectively, which were lower than those in group B (65.0% and 25.0%, respectively) Significance (P <0.05), A, B two groups of different treatment options after the difference is not significant. Conclusion The IEA regimen is effective in treating refractory acute lymphoblastic leukemia with definite curative effect, obvious effect and few side effects. It is worth to be popularized in clinic.